公开(公告)号：WO2022246055A1

公开(公告)日：2022-11-24

申请号：PCT/US2022/030014

申请日：2022-05-19

Applicant: AMGEN INC.

Inventor： GOSWAMI, Devrishi ,  ZHANG, Jun ,  PIEDMONTE, Deirdre ,  PADMAKUMAR, Vikashni ,  LE, David ,  SANTOS, Maria, Raquel ,  QI, Wei

IPC: B65B3/00

Abstract: A method of filling a vial. The method includes providing a pump corresponding to a vial and setting a drip retraction parameter for the pump to any value equal to or less than 20 degrees. The method also includes setting a no adjustment limit for a fill weight of the vial to T1, with T1 being at or in a range of about 2% more or less than a fill weight of a target fill weight T0, wherein a process performance index Cpk (Cpk) for the vial throughout a fill cycle exceeds a minimum value.

公开(公告)号：WO2021243284A1

公开(公告)日：2021-12-02

申请号：PCT/US2021/034987

申请日：2021-05-28

Applicant: AMGEN INC.

Inventor： IP, Anna ,  PATEL, Ketaki ,  TALLEY, Clea ,  TREUHEIT, Michael J. ,  ZHANG, Jun

IPC: A61K39/395 ,  A61P7/00 ,  C07K16/18

Abstract: Antibody formulations and methods of making and using such formulations are provided herein. The formulation can be for intravenous administration. In some embodiments, the formulation is for subcutaneous administration. In some embodiments, the formulation comprises an anti-C5 antibody, such as eculizumab.

公开(公告)号：WO2018204907A1

公开(公告)日：2018-11-08

申请号：PCT/US2018/031347

申请日：2018-05-07

Applicant: AMGEN INC.

Inventor： ABEL, Jeff ,  CUI, Lingwen ,  GOSWAMI, Devrishi ,  HUH, Joon ,  JAGANNATHAN, Bharadwaj ,  KANAPURAM, Sekhar ,  MCAULEY, Arnold ,  SCHNEIDER, Michael ,  SETHURAMAN, Ananthakrishnan, G. ,  TREUHEIT, Michael ,  ZHANG, Jun

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/00

Abstract: The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.

公开(公告)号：WO2022036126A2

公开(公告)日：2022-02-17

申请号：PCT/US2021/045784

申请日：2021-08-12

Applicant: AMGEN INC.

Inventor： MURRAY, Justin K. ,  ZHANG, Jun ,  HOMANN, Oliver ,  LONG, Jason C. ,  MEADE, Bryan

IPC: C12N15/113 ,  A61K31/713 ,  A61K31/7125 ,  A61P1/16 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/317 ,  C12N2310/332 ,  C12N2310/343 ,  C12N2310/346 ,  C12N2320/11 ,  C12N2320/30 ,  C12Q1/6869

Abstract: The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.

公开(公告)号：WO2018039647A1

公开(公告)日：2018-03-01

申请号：PCT/US2017/048757

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： OLLMANN, Michael ,  LI, Yang ,  ZHANG, Jun ,  BISWAS, Kaustav ,  HOMANN, Oliver ,  MIRANDA, Leslie P. ,  MURRAY, Justin K. ,  WU, Bin ,  YOON, Oh Kyu ,  ALLEN, John Gordon ,  NETIROJJANAKUL, Chawita ,  CHENG, Yuan

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

Abstract translation: 本发明涉及用于减少ASGR1基因表达的RNAi构建体。 还描述了使用这种RNAi构建体来治疗或预防心血管疾病（例如冠状动脉疾病和心肌梗塞）并降低血清非HDL胆固醇水平的方法。